Pharvaris N.V.
PHVS · NASDAQ
Bulios Fair Price
$29.67
17.6% downside
Current Price
$36.02
According to Bulios Fair Price, PHVS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Pharvaris N.V. (PHVS) is a biotechnology company focused on developing innovative drugs for the treatment of rare diseases, particularly angioedema disorders. The company utilizes advanced technologies and modern approaches to discover new drug candidates that can improve the quality of life for patients suffering from these conditions. Pharvaris N.V. is focused on developing drugs targeting specific molecular mechanisms that can provide effective treatment with minimal side effects. Shares of Pharvaris N.V. (PHVS) could be an intriguing investment opportunity for investors monitoring the biotechnology sector and seeking companies with the potential to change the therapeutic paradigm for a range of diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Berndt Modig
Employees
148
Headquarters
Zug
Upcoming events
Earnings
Upcoming earnings report